This data in conjunction with a recent finding that Hsp40 is involved in regulation of ARv13 and p5328 makes DNAJA1 inhibition an ideal choice as a novel therapeutic target in Prostate Cancer. This evidence concerns the gene DNAJA1 and prostate cancer.